ABC Family Arquivos Brasileiros de Cardiologia International Journal of Cardiovascular Sciences ABC Heart Failure & Cardiomyopathy ABC Imagem Cardiovascular
Português English
ABC Family
Português English
  • About
    • About ABC Family
    • Internal Regulation
    • Editorial Board
    • Brazilian Society of Cardiology (SBC)
  • Issues
  • SBC Guidelines
  • Content
    • Videos
    • Podcasts
    • News
  • About
    • About ABC Family
    • Internal Regulation
    • Editorial Board
    • Brazilian Society of Cardiology (SBC)
  • Issues
  • SBC Guidelines
  • Content
    • Videos
    • Podcasts
    • News

ABC Family

  • ABC Family
  • Arquivos Brasileiros de Cardiologia
  • International Journal of Cardiovascular Sciences
  • ABC Heart Failure & Cardiomyopathy
  • ABC Imagem Cardiovascular
Search in

No content found.

Journals
Ordering
Article types
Others

  1. Home
  2. Keyword: Valsartan/therapeutic use
IJCS
Viewpoint

PARAGON-HF: Lessons Learned and Perspectives

José Francisco Kerr Saraiva et al. Isadora de Oliveira

An estimated 6.5 million Americans aged 20 and over have heart failure (HF) and projections show that the prevalence of HF will increase by 46% from 2012 to 2030, resulting in over 8 million people with HF.

Patients with HF can be stratified into different categories of left ventricular ejection fraction (LVEF), presenting different phenotypes in terms of demographics, clinical presentation, etiology and outcomes. The current classification comprises HF with reduced ejection fraction (EF) [EF ≤ 40% (HFrEF)], with intermediate EF [EF 40-50% (HFiEF), and preserved EF [EF ≥ 50% (HFpEF).,

[…]

  • Dysfunction Left Ventricular/abnormalities
  • Echocardiography/methods
  • Heart Failure/physiopathology
  • Indicators of Morbidity and Mortality
  • Neprilysin/therapeutic use
  • Risk Factors
  • Valsartan/therapeutic use
Read Full Article
Creative Commons Attribution (CC BY) Creative Commons license
17/04/2020 DOI: 10.36660/ijcs.20190222
ABC
Viewpoint

The Diuretic Effect of Sacubitril/Valsartan Might Be Clinically Relevant

Luís Beck-da-Silva et al. Luís E. Rohde

Recently, patients with heart failure have been prescribed a novel and innovative drug. Sacubitril/valsartan is a new drug modality that brings a 16% reduction in total mortality, a 20% reduction in cardiovascular mortality and 21% reduction in hospital admissions due to heart failure. The benefit is undoubtedly clinically relevant and the clinical trial which have shown such benefit have achieved an unprecedented statistical significance.

The mechanism of action of sacubitril/valsartan combines the well-known vasodilatory effect of valsartan associated with the neutral endopeptidase (NEP) inhibition effect of sacubitril, which will ultimately result in increased serum levels of natriuretic peptides, increased action of endogenous natriuretic peptides in target tissues by prolonging its tissue half-life, and consequently increased vasodilatory, anti-proliferative and natriuretic effects.

[…]

  • Aminobutyrates/pharmacology
  • Angiotensin Receptor Antagonists/pharmacology
  • Heart Failure
  • Natriuretic Peptides/physiology
  • Tetrazoles/farmacologia
  • Valsartan/therapeutic use
Read Full Article
Creative Commons Attribution (CC BY) Creative Commons license
15/07/2019 DOI: 10.5935/abc.20190080 Views 2

How to cite this article

EndNote RIS

Electronic Document Format (Vancouver)

Saraiva JFK, Oliveira I. PARAGON-HF: Lessons Learned and Perspectives. International Journal of Cardiovascular Sciences 2020;33(3):278-81.

Electronic Document Format (ABNT)

Saraiva, José Francisco Kerr; Oliveira, Isadora de. PARAGON-HF: Lessons Learned and Perspectives. International Journal of Cardiovascular Sciences, v. 33, n. 3, p. 278-281, Apr. 2020.

Electronic Document Format (APA)

Saraiva, J. F. K., & Oliveira, I. (2020). PARAGON-HF: Lessons Learned and Perspectives. International Journal of Cardiovascular Sciences, 33(3), 278-281.

Electronic Document Format (ISO)

Saraiva, José Francisco Kerr and Oliveira, Isadora de. PARAGON-HF: Lessons Learned and Perspectives. International Journal of Cardiovascular Sciences [online]. 2020, vol. 33, n. 3, [cited 2026-10-14], pp. 278-281. Available from: <https://journals.cardiol.br/en/article/paragon-hf-lessons-learned-and-perspectives/>. ISSN 2359-4802

EndNote RIS

Electronic Document Format (Vancouver)

Beck-da-Silva L, Rohde LE. The Diuretic Effect of Sacubitril/Valsartan Might Be Clinically Relevant. Arquivos Brasileiros de Cardiologia 2019;112(6):791-2.

Electronic Document Format (ABNT)

Beck-da-Silva, Luís; Rohde, Luís E.. The Diuretic Effect of Sacubitril/Valsartan Might Be Clinically Relevant. Arquivos Brasileiros de Cardiologia, v. 112, n. 6, p. 791-792, Jul. 2019.

Electronic Document Format (APA)

Beck-da-Silva, L., & Rohde, L. E. (2019). The Diuretic Effect of Sacubitril/Valsartan Might Be Clinically Relevant. Arquivos Brasileiros de Cardiologia, 112(6), 791-792.

Electronic Document Format (ISO)

Beck-da-Silva, Luís and Rohde, Luís E.. The Diuretic Effect of Sacubitril/Valsartan Might Be Clinically Relevant. Arquivos Brasileiros de Cardiologia [online]. 2019, vol. 112, n. 6, [cited 2026-10-14], pp. 791-792. Available from: <https://journals.cardiol.br/en/article/the-diuretic-effect-of-sacubitril-valsartan-might-be-clinically-relevant/>. ISSN 0066-782X

  • About ABC Family
  • Internal Regulation
  • Editorial Board
  • Brazilian Society of Cardiology (SBC)

Issues

SBC Guidelines

  • Videos
  • Podcasts
  • News